Olney Richard S, Botto Lorenzo D
Birth Defects Res A Clin Mol Teratol. 2012 Dec;94(12):965-9. doi: 10.1002/bdra.23103. Epub 2012 Nov 27.
Newborn screening for critical congenital heart defects, added in September 2011 to the Recommended Uniform Screening Panel in the United States, is a new public health priority and has particular relevance for state birth defects surveillance programs. In this commentary, we review the background to potential involvement by birth defects programs with screening, and detail key questions that these programs can evaluate: (1) health outcomes after newborn screening among affected children; (2) missed primary targets of screening (i.e., affected children who were not screened or had false-negative screens); (3) burden and screening accuracy for secondary targets; (4) the role of altitude, sociodemographic characteristics, and other special circumstances; (5) the contribution of prenatal and clinical diagnoses before newborn screening; and (6) costs and service utilization. To address these issues, monitoring programs will need to pay particular attention to: (1) data sources and quality; (2) timeliness; (3) long-term follow-up for comprehensive outcomes; (4) reporting standards; and (5) state and national program coordination. Although some aspects of involvement with these screening programs will require new partnerships and paradigm shifts in birth defects program operations, the visibility of these screening programs among stakeholders will also provide birth defects programs with new opportunities to demonstrate their usefulness.
2011年9月,对严重先天性心脏病的新生儿筛查被纳入美国推荐统一筛查项目,这是一项新的公共卫生重点工作,对各州出生缺陷监测项目具有特殊意义。在本评论中,我们回顾了出生缺陷项目参与筛查的潜在背景,并详细阐述了这些项目可评估的关键问题:(1)受影响儿童经新生儿筛查后的健康结局;(2)筛查的主要目标遗漏情况(即未接受筛查或筛查结果为假阴性的受影响儿童);(3)次要目标的负担和筛查准确性;(4)海拔、社会人口学特征及其他特殊情况的作用;(5)新生儿筛查前产前诊断和临床诊断的贡献;以及(6)成本和服务利用情况。为解决这些问题,监测项目需要特别关注:(1)数据来源和质量;(2)及时性;(3)综合结局的长期随访;(4)报告标准;以及(5)州和国家项目的协调。尽管参与这些筛查项目的某些方面需要建立新的伙伴关系,并在出生缺陷项目运作中实现范式转变,但这些筛查项目在利益相关者中的知名度也将为出生缺陷项目提供新的机会来证明其有用性。